ELTX
Elicio Therapeutics, Inc. NASDAQ Listed Feb 5, 2021$1.82
-1.45%
vs $1.85
Mkt Cap $34.8M
52w Low $1.71
0.8% of range
52w High $16.00
50d MA $2.66
200d MA $7.53
P/E (TTM)
—
EV/EBITDA
—
P/B
17.1x
Debt/Equity
8.9x
ROE
-2418.8%
P/FCF
-0.8x
RSI (14)
19.50
ATR (14)
$0.13
Beta
1.88
50d MA
$2.66
200d MA
$7.53
Avg Volume
352.1K
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
451 D Street · Boston, MA 02210 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.47 | -0.49 | -4.3% | 10.90 | +3.7% | +11.9% | -0.3% | +0.2% | -4.1% | +2.6% | — |
| Nov 13, 2025 | AMC | -0.62 | -0.60 | +3.2% | 9.11 | -2.9% | -2.2% | -2.1% | -1.7% | -5.5% | -1.4% | — |
| Aug 7, 2025 | AMC | -0.69 | -0.66 | +4.3% | 9.07 | +3.1% | +1.4% | -6.0% | +8.7% | +2.7% | +3.0% | — |
| May 13, 2025 | AMC | -0.67 | -0.87 | -29.9% | 5.71 | +0.7% | -5.3% | -1.7% | +0.2% | +9.6% | -5.8% | — |
| Mar 31, 2025 | AMC | -0.94 | -1.02 | -8.5% | 6.16 | -0.2% | -19.6% | +4.4% | +6.4% | +9.3% | -11.5% | — |
| Nov 13, 2024 | AMC | -0.81 | -1.39 | -71.6% | 5.20 | +0.0% | +4.8% | +0.6% | -3.5% | -1.7% | -3.7% | — |
| Aug 13, 2024 | AMC | -0.96 | -0.64 | +33.3% | 4.53 | +3.3% | -5.3% | +0.5% | +2.1% | +4.1% | -1.3% | — |
| May 15, 2024 | AMC | -1.09 | -1.15 | -5.5% | 10.40 | +10.1% | -9.8% | +7.1% | -1.9% | -10.1% | +0.0% | — |
| Feb 13, 2024 | AMC | -0.78 | -1.75 | -124.4% | 4.33 | -1.8% | -6.2% | +3.0% | -0.5% | +1.0% | -5.0% | — |
| Nov 9, 2023 | AMC | -0.80 | -1.27 | -58.8% | — | — | — | — | — | — | — | — |
| Aug 11, 2023 | AMC | -5.70 | -2.61 | +54.2% | — | — | — | — | — | — | — | — |
| May 10, 2023 | AMC | -0.54 | -0.15 | +72.2% | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 18 | Ladenburg Thalmann | Reiterates | Buy | $12 | $4.71 | $4.21 | -10.6% | -18.3% | +7.5% | -0.7% | -3.2% | -5.8% |
| Jun 10 | B. Riley Securities | Initiates | Buy | $27 | $14.20 | $14.74 | +3.8% | +0.7% | -2.5% | +6.5% | -72.5% | -32.4% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.90 | $11.30 | +3.7% | +11.9% | -0.3% | +0.2% | -4.1% | +2.6% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.05 | $9.18 | +1.4% | +2.8% | +0.4% | -1.1% | +0.9% | +5.3% |
| Apr 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.95 | $5.04 | +1.8% | +4.4% | +6.4% | +9.3% | -11.5% | -2.4% |
| Aug 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.46 | $4.47 | +0.2% | -2.7% | +1.4% | -8.6% | -1.0% | +0.5% |
| Jun 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.98 | $8.06 | +1.0% | +1.3% | -3.1% | +2.2% | +1.9% | +4.2% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.86 | $8.73 | -1.5% | +0.0% | -0.1% | -5.0% | -4.3% | -5.3% |
| May 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.20 | $9.20 | +0.0% | -3.8% | +1.7% | -0.2% | +0.0% | +0.8% |
| Apr 1 | Oppenheimer | Maintains | Perform → Perform | — | $7.60 | $6.83 | -10.1% | -6.3% | +4.2% | -0.7% | +2.0% | +17.7% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.28 | $5.38 | +1.9% | -3.8% | -3.7% | -4.1% | -11.3% | -10.1% |
No insider trades available.
8-K · 8.01
!! High
Elicio Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Sep 14
8-K · 2.02
!! High
Elicio Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aug 13
8-K · 8.01
!! High
Elicio Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jul 2
8-K · 7.01
! Medium
Elicio Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Elicio Therapeutics disclosed a presentation regarding its operations and strategy, though specific business details or developments are not detailed in this regulatory filing.
Jun 24
8-K · 8.01
!! High
Elicio Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Elicio Therapeutics issued a press release regarding a material event, though the specific announcement details are not disclosed in this 8-K summary filing.
Jun 17
8-K · 8.01
!! High
Elicio Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Elicio Therapeutics announced Phase 2 AMPLIFY-7P trial results via press release and conference call presentation, providing investors clinical data on its therapeutic candidate's efficacy and safety profile.
Jun 15
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
ELTX secured a $40M at-the-market offering facility, providing flexible capital access to fund operations or acquisitions without immediate shareholder dilution concerns, though future equity issuance remains likely.
Mar 16
8-K
Unknown — 8-K Filing
ELTX has sufficient cash through Q3 2026 to complete its key AMPLIFY-7P Phase 2 analysis, reducing near-term dilution risk and providing a critical catalyst for investors within six months.
Mar 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | 766,005 | $3M | New | Jun 2026 |
| 2 | Vanguard Capital Management Llc | 572,151 | $2M | Added | Jun 2026 |
| 3 | Marshall Wace, Llp | 74,512 | $797K | Reduced | Mar 2026 |
| 4 | Susquehanna International Group, Llp | 70,804 | $757K | Added | Mar 2026 |
| 5 | Northern Trust Corp | 59,734 | $639K | Added | Mar 2026 |
| 6 | Ubs Group Ag | 33,769 | $361K | Added | Mar 2026 |
| 7 | Vanguard Portfolio Management Llc | 88,905 | $348K | New | Jun 2026 |
| 8 | Iridian Asset Management Llc/ct | 30,051 | $321K | New | Mar 2026 |
| 9 | Cresset Asset Management, Llc | 26,925 | $295K | New | Sep 2025 |
| 10 | Morgan Stanley | 29,106 | $232K | Added | Dec 2025 |
| 11 | Hrt Financial Lp | 21,611 | $231K | New | Mar 2026 |
| 12 | Bank Of America Corp /de/ | 15,333 | $164K | Added | Mar 2026 |
| 13 | Qube Research & Technologies Ltd | 12,482 | $133K | Reduced | Mar 2026 |
| 14 | Raymond James Financial Inc | 11,100 | $119K | New | Mar 2026 |
| 15 | Leonteq Securities Ag | 20,000 | $78K | New | Jun 2026 |
| 16 | Nuveen, Llc | 17,888 | $70K | New | Jun 2026 |
| 17 | Citigroup Inc | 17,726 | $69K | New | Jun 2026 |
| 18 | Bnp Paribas Financial Markets | 6,344 | $68K | Added | Mar 2026 |
| 19 | Meyer Handelman Co | 13,899 | $54K | New | Jun 2026 |
| 20 | Wealth Enhancement Advisory Services, Llc | 11,972 | $42K | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 17
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 58,772 | $763K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 27,993 | $299K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 21,289 | $244K | May 2026 |
| 4 | Fidelity Series Total Market Index Fund | 16,617 | $190K | May 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 14,357 | $186K | Feb 2026 |
| 6 | Small Cap Core Fund | 10,086 | $39K | Jun 2026 |
| 7 | Small Cap Index Fund | 6,744 | $26K | Jun 2026 |
| 8 | Small-Cap Index Portfolio | 6,525 | $26K | Jun 2026 |
| 9 | Victory Extended Market Index Fund | 1,142 | $9K | Jan 2026 |
| 10 | DWS Small Cap Index VIP | 1,989 | $8K | Jun 2026 |
| 11 | Nationwide Small Cap Index Fund | 2,009 | $6K | Jul 2026 |
| 12 | CVT Russell 2000 Small Cap Index Portfolio | 1,176 | $5K | Jun 2026 |
| 13 | PD Small-Cap Growth Index Portfolio | 1,089 | $4K | Jun 2026 |
| 14 | ULTRA SMALL CAP PROFUND | 167 | $468 | Jul 2026 |
| 15 | Guggenheim Active Allocation Fund | 12 | $156 | Feb 2026 |
| 16 | SMALL-CAP PROFUND | 11 | $31 | Jul 2026 |
| 17 | Russell 2000(R) 1.5x Strategy Fund | 4 | $16 | Jun 2026 |
Valuation
Market Cap
$34.8M
Enterprise Value
$19.2M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.08x
P/B
17.07x
P/S
—
P/FCF
-0.77x
EV/EBITDA
—
Shares Out
15.3M
Financials (TTM)
Revenue
$0
Net Income
-$37.8M
EBITDA
-$40.5M
Free Cash Flow
-$37.0M
Op Cash Flow
-$37.0M
EPS Basic
$-2.58
EPS Diluted
$-2.13
EPS Forward
$-1.50
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$25.9M
Total Liab.
$24.2M
Total Equity
$1.6M
Cash
$18.6M
LT Debt
$9.4M
Book Value/Sh
$0.11
Debt/Equity
8.87x
Current Ratio
2.38
Quick Ratio
2.38
Returns & Growth
ROE
-2418.8%
ROA
-153.0%
ROIC
-201.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+39.3%
Price Returns
2W
-7.5%
1M
-34.9%
3M
-53.8%
6M
-82.3%
12M
-82.9%
Technicals
52W High
$16.00
52W Low
$1.71
50d MA
$2.66
200d MA
$7.53
RSI (14)
19.50
ATR (14)
$0.13
Beta
1.88
Avg Volume
352K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$17.00
High
$17.00
Low
$17.00
Median
$17.00
Data updated apr 25, 2026 6:58am
· Source: financialmodelingprep.com